Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Application based on results from the TROPION-Breast01 Phase III trial
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
The validations confirm the completion of the applications and commence the scientific review process
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Eugia Pharma Specialities restarts production at terminally sterilized product lines
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
Both the Ministries signed MoU for anaemia control among adolescent girls using Ayurveda interventions
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Subscribe To Our Newsletter & Stay Updated
